FindTrial
Sign In

ONCOS-102

BIOLOGICAL5 trials

Sponsors

Targovax Oy, Ludwig Institute for Cancer Research

Conditions

Advanced or Unresectable Melanoma Progressing After PD1 BlockadeAppendiceal CancerColorectal CancerMalignant Solid TumourMelanomaOvarian CancerTo Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy

Phase 1

ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
CompletedNCT01598129
Targovax OyMalignant Solid Tumour
Start: 2012-04-30End: 2013-10-31Updated: 2016-10-24
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
NCT02879669
Targovax OyTo Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
Start: 2016-06-30Updated: 2020-10-08
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
CompletedNCT02963831
Ludwig Institute for Cancer ResearchAppendiceal Cancer, Colorectal Cancer, Ovarian Cancer
Start: 2017-09-07End: 2022-06-25Updated: 2022-12-22
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
CompletedNCT03003676
Targovax OyAdvanced or Unresectable Melanoma Progressing After PD1 Blockade
Start: 2016-12-31End: 2020-10-31Updated: 2021-11-08

Phase 2

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
WithdrawnNCT05561491
Targovax OyMelanoma
Start: 2024-01-31End: 2027-06-30Updated: 2023-06-22

Related Papers

Granular analysis of individual immune-related gene expression in a randomized phase I/II study of the oncolytic adenovirus, ONCOS-102, in combination with pemetrexed/cisplatin (P/C) in patients (pts) with unresectable malignant pleural mesothelioma (MPM).
Journal of Clinical Oncology2023-06-011 citations
615 Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma
Regular and Young Investigator Award Abstracts2022-11-012 citations
Abstract 1983: Modulation of immune gene expression by intra-tumoral oncolytic adenovirus ONCOS-102 is associated with clinical response in anti-PD-1 refractory/resistant melanoma
Cancer Research2022-06-15
Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.
Journal of Clinical Oncology2022-06-015 citations
Final survival outcomes and immune biomarker analysis of a randomized, open-label, phase I/II study combining oncolytic adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients with unresectable malignant pleural mesothelioma (MPM).
Journal of Clinical Oncology2022-06-011 citations
368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors
Regular and Young Investigator Award Abstracts2021-11-01
462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data
Regular and Young Investigator Award Abstracts2021-11-01
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
Regular and Young Investigator Award Abstracts2020-11-017 citations
Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.
Journal of Clinical Oncology2020-05-207 citations
Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)
Cancer Immunology Research2019-02-011 citations
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
OncoImmunology2018-10-2998 citations
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model
Journal of Medical Virology2018-05-2441 citations
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
PLoS ONE2017-08-1043 citations
Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model
International Journal of Cancer2016-06-1156 citations
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
Journal for ImmunoTherapy of Cancer2016-03-02198 citations
An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors.
Journal of Clinical Oncology2015-05-201 citations